Acute On Chronic Liver Failure Market to 2030 – Insight, Epidemiology and Forecast – ResearchAndMarkets.com
November 20, 2020DUBLIN–(BUSINESS WIRE)–The “Acute On Chronic Liver Failure (ACLF) Market Insight, Epidemiology and Market Forecast – 2030” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of acute-on-chronic liver failure (ACLF) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The acute-on-chronic liver failure (ACLF) market report provides analysis regarding current treatment practices, emerging drugs like Albutein 5% (PE-A 5%) and Hepastem, other promising therapies market share of the individual therapies, and historical, current, and forecasted ACLF market size from 2017 to 2030, segmented by seven major markets.
Furthermore, the report also covers current acute-on-chronic liver failure treatment practice/algorithm, guidelines, market drivers, market barriers, and unmet medical needs to curate the best opportunities. It also assesses the underlying potential of the market.
Acute-on-Chronic Liver Failure is a clinical syndrome observed in patients with already existing liver disease. It is characterized by a precipitating event, multiorgan failure, and is associated with short-term mortality. ACLF has been defined differently by various organizations, including Asia Pacific (APASL), European and North American consortia, and the World Gastroenterology Organization. These definitions differ in terms of acute event duration, precipitating events, presenting features, underlying liver disease, and definitions of organ failure.
Furthermore, ACLF is classified into three groups, according to the underlying liver disease ACLF: type A ACLF (patients with underlying non-cirrhotic chronic liver disease), type B ACLF (patients with previously compensated cirrhosis), and C ACLF (patients with previous decompensated cirrhosis). Diagnosis involves liver biopsy and the use of prognostic scores. Biomarkers are needed to optimize diagnosis and understand the pathophysiology of complications.
Treatment:
There is no specific treatment for patients with ACLF, and management is based on organ support, management of complications associated with specific etiologies, and liver transplantation. New treatment strategies based on liver support systems, immunomodulatory treatments, and stem cell therapy are being evaluated in clinical studies.
This chapter covers the details of conventional and current medical therapies available to treat acute-on-chronic liver failure. It also provides acute-on-chronic liver failure treatment guidelines across the United States and Europe.
The publisher’s acute-on-chronic liver failure market report gives a thorough understanding of the disease by including details such as disease definition, etiology, types, pathophysiology, biomarkers, and diagnosis. It also provides Acute-on-Chronic Liver Failure treatment patterns and treatment guidelines in the US and Europe.
Epidemiology:
The acute-on-chronic liver failure (ACLF) epidemiology chapters provide insights about historical and current ACLF patient pool and forecasted trends for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Acute-on-chronic liver failure epidemiology is segmented by the cases of Acute-on-chronic liver failure, cases of acute-on-chronic liver failure by grades, organ failures associated with acute-on-chronic liver failure, potential precipitating events of acute-on-chronic liver failure. Besides, the report includes a thorough analysis of all segments.
According to the publisher’s, the total prevalent acute-on-chronic liver failure population in seven major markets was 60,521 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).
Among all the seven major markets, total prevalent cases for Acute-on-Chronic Liver Failure were the highest cases for ACLF were in Germany, followed by the United States. Italy accounted for the least number of cases among the 7MM.
Drug Chapters:
This segment encloses the detailed analysis of the drugs in the Acute-on-Chronic Liver Failure pipeline. It also helps understand the Acute-on-Chronic Liver Failure clinical trial details, expressive pharmacological action, the included drug’s agreements, and the latest news and press releases.
Currently, there is no specific effective treatment available for patients with ACLF. Therefore, management relies on early identification, the treatment of precipitating factors (bacterial infections, treatment for HBV, corticosteroids in alcoholic hepatitis), and support treatment for the various types of organ failures. It also includes determining the prognosis pattern and the subsequent need for liver support, including possible liver transplantation. Liver transplantation (LT) remains the definitive treatment for patients with ACLF.
Report Highlights:
- In the coming years, the acute-on-chronic liver failure market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.
- the in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Companies Mentioned
- Grifols Therapeutics
- RHEACELL
- Versantis
- Martin Pharmaceuticals
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/y2688a
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900